Navigation Links
Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/9/2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.  

The live presentation takes place on Thursday, May 16 at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600 or ir@neurocrine.com.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for one month.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
2. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
3. Neurocrine Biosciences Reports Third Quarter 2012 Results
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
6. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
7. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
11. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 30, 2020 , ... ... life sciences industry, today announced the release of its signature product called ... Science Liaisons (MSLs) and other field medical professionals. , Beacon helps ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter implantation, ... surgery is only the beginning of a successful study, while protecting and accessing the ... Gien, Global Head of Surgery from Envigo in a live webinar ...
(Date:7/18/2020)... Ohio (PRWEB) , ... July 16, 2020 , ... ... data solutions to aid in the early detection and prevention of high-burden diseases, ... to enable US-based hospitals and healthcare organizations to utilize existing data in order ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a ... its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in ...
(Date:8/26/2020)... ... 2020 , ... Modality Solutions, a biopharmaceutical cold chain validation engineering ... The list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality ... list, reported three-year revenue growth of 71 percent. , The Inc. 5000 list ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) ... severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 ...
Breaking Biology News(10 mins):